Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIA-1 is a specific isolate of the **Chicken Infectious Anemia Virus (CIAV)**, a small, non-enveloped DNA virus belonging to the genus *Gyrovirus*. It is primarily utilized in the development of veterinary vaccines to protect poultry from chicken infectious anemia, a condition characterized by lymphoid atrophy, aplastic anemia, and severe immunosuppression. Research has focused on using the CIA-1 strain in **immune complex (IC) vaccines**, where the virus is bound to specific neutralizing antibodies. This approach allows for the vaccination of young chicks or *in ovo* administration, effectively bypassing interference from maternal antibodies and providing protection against field strains of the virus. The CIA-1 isolate is characterized by specific amino acid sequences in its VP1, VP2, and VP3 proteins that influence its replication rate and cell tropism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chicken infectious anemia virus vaccine (CIA-1 strain).